Immunocore (IMCR) announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) ...

Immunocore (IMCR) Holdings announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C which is a half-life extended ImmTAC candidate. IMC-P115C was developed to improve patient ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 17 December 2024) Immunocore Holdings plc (IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering ...

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic ...

Immunocore (IMCR) announces that the first patient has been treated in the Phase 1/2 trial of its novel ImmTAC candidate, IMC-R117C, targeting PIWIL1 in colorectal and other gastrointestinal cancers.

The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First ...